Expression of Dicer and Drosha in triple-negative breast cancer

Journal of Clinical Pathology

Volumn 65, Issue 4, 2012, Pages 320-326

  Passon, Nadia ^a   Gerometta, Anna ^a   Puppin, Cinzia ^a   Lavarone, Elisa ^a   Puglisi, Fabio ^a   Tell, Gianluca ^a   Di Loreto, Carla ^a   Damante, Giuseppe ^a  

^a UNIVERSITY OF UDINE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

DICER; DROSHA PROTEIN; MESSENGER RNA; PROTEIN; UNCLASSIFIED DRUG;

AGED; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOPLASM; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MYOEPITHELIUM CELL; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STEADY STATE; WESTERN BLOTTING;

BLOTTING, WESTERN; BREAST NEOPLASMS; CELL LINE, TUMOR; CYCLOPHILIN A; DEAD-BOX RNA HELICASES; DOWN-REGULATION; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; MITOCHONDRIAL PROTEINS; REAL-TIME POLYMERASE CHAIN REACTION; RIBONUCLEASE III; RIBOSOMAL PROTEINS; RNA, MESSENGER;

EID: 84858706563     PISSN: 00219746     EISSN: 14724146     Source Type: Journal    
DOI: 10.1136/jclinpath-2011-200496     Document Type: Article

References (41)

1. Foulkes WD, Smith IE, Reis-Filho JS. Triple-negative breast cancer. N Engl J Med 2010;363:1938-48.
2. Rakha EA, Elsheikh SE, Aleskandarany MA, et al. Triple-negative breast cancer: distinguishing between basal and nonbasal subtypes. Clin Cancer Res 2009;15:2302-10.
3. Perou CM, Sørlie T, Eisen MB, et al. Molecular portraits of human breast tumours. Nature 2000;406:747-52.
4. Badve S, Dabbs DJ, Schnitt SJ, et al. Basal-like and triple-negative breast cancers: a critical review with an emphasis on the implications for pathologists and oncologists. Mod Pathol 2011;24:157-67.
5. Rakha EA, Reis-Filho JS, Ellis IO. Basal-like breast cancer: a critical review. J Clin Oncol 2008;26:2568-81.
6. Reis-Filho JS, Tutt AN. Triple negative tumours: a critical review. Histopathology 2008;52:108-18. (Pubitemid 350265179)
7. Andreetta C, Minisini AM, Miscoria M, et al. First-line chemotherapy with or without biologic agents for metastatic breast cancer. Crit Rev Oncol Hematol 2010;76:99-111.
8. Kennecke H, Yerushalmi R, Woods R, et al. Metastatic behavior of breast cancer subtypes. J Clin Oncol 2010;28:3271-7.
9. Liedtke C, Mazouni C, Hess KR, et al. Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J Clin Oncol 2008;26:1275-81.
10. Tan DS, Marchió C, Jones RL, et al. Triple negative breast cancer: molecular profiling and prognostic impact in adjuvant anthracycline-treated patients. Breast Cancer Res Treat 2008;111:27-44. (Pubitemid 352009225)
11. Hugh J, Hanson J, Cheang MC, et al. Breast cancer subtypes and response to docetaxel in node-positive breast cancer: use of an immunohistochemical definition in the BCIRG 001 trial. J Clin Oncol 2009;27:1168-76.
12. Carey LA, Perou CM, Livasy CA, et al. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA 2006;295:2492-502. (Pubitemid 43854964)
13. Ke XS, Liu CM, Liu DP, et al. MicroRNAs: key participants in gene regulatory networks. Curr Opin Chem Biol 2003;7:516-23.
14. Miranda KC, Huynh T, Tay Y, et al. A pattern-based method for the identification of microRNA binding sites and their corresponding heteroduplexes. Cell 2006;126:1203-17. (Pubitemid 44380294)
15. Tsai LM, Yu D. MicroRNAs in common diseases and potential therapeutic applications. Clin Exp Pharmacol Physiol 2010;37:102-7.
16. Iorio MV, Croce CM. MicroRNAs in cancer: small molecules with a huge impact. J Clin Oncol 2009;27:5848-56.
17. Rothé F, Ignatiadis M, Chaboteaux C, et al. Global MicroRNA expression profiling identifies MiR-210 associated with tumor proliferation, invasion and poor clinical outcome in breast cancer. PLoS One 2011;6:e20980.
18. Murchison EP, Hannon GJ. miRNAs on the move: miRNA biogenesis and the RNAi machinery. Curr Opin Cell Biol 2004;16:223-9. (Pubitemid 38610401)
19. Perron MP, Provost P. Protein components of the microRNA pathway and human diseases. Methods Mol Biol 2009;487:369-85.
20. Merritt WM, Lin YG, Han LY, et al. Dicer, Drosha, and outcomes in patients with ovarian cancer. N Engl J Med 2008;359:2641-50.
21. Sand M, Gambichler T, Skrygan M, et al. Expression levels of the microRNA processing enzymes Drosha and dicer in epithelial skin cancer. Cancer Invest 2010;28:649-53.
22. Wu H, Xu H, Miraglia LJ, et al. Human RNase III is a 160-kDa protein involved in preribosomal RNA processing. J Biol Chem 2000;275:36957-65. (Pubitemid 32002110)
23. MacRae IJ, Zhou K, Doudna JA. Structural determinants of RNA recognition and cleavage by Dicer. Nat Struct Mol Biol 2007;14:934-40. (Pubitemid 47525174)
24. Karube Y, Tanaka H, Osada H, et al. Reduced expression of Dicer associated with poor prognosis in lung cancer patients. Cancer Sci 2005;96:111-15. (Pubitemid 40425386)
25. Grelier G, Voirin N, Ay AS, et al. Prognostic value of Dicer expression in human breast cancers and association with the mesenchymal phenotype. Br J Cancer 2009;101:673-83.
26. Chiosea SI, Barnes EL, Lai SY, et al. Mucoepidermoid carcinoma of upper aerodigestive tract: clinicopathologic study of 78 cases with immunohistochemical analysis of Dicer expression. Virchows Arch 2008;452:629-35.
27. Bild AH, Yao G, Chang JT, et al. Oncogenic pathway signatures in human cancers as a guide to targeted therapies. Nature 2006;439:353-7. (Pubitemid 43128862)
28. Chin K, DeVries S, Fridlyand J, et al. Genomic and transcriptional aberrations linked to breast cancer pathophysiologies. Cancer Cell 2006;10:529-41. (Pubitemid 44854748)
29. Ivshina AV, George J, Senko O, et al. Genetic reclassification of histologic grade delineates new clinical subtypes of breast cancer. Cancer Res 2006;66:10292-301. (Pubitemid 44799747)
30. Pawitan Y, Bjohle J, Amler L, et al. Gene expression profiling spares early breast cancer patients from adjuvant therapy: derived and validated in two population-based cohorts. Breast Cancer Res 2005;7:R953-64.
31. Chiosea S, Jelezcova E, Chandran U, et al. Up-regulation of dicer, a component of the MicroRNA machinery, in prostate adenocarcinoma. Am J Pathol 2006;169:1812-20. (Pubitemid 351182010)
32. Sugito N, Ishiguro H, Kuwabara Y, et al. RNASEN regulates cell proliferation and affects survival in esophageal cancer patients. Clin Cancer Res 2006;12:7322-8. (Pubitemid 46095404)
33. Dedes KJ, Natrajan R, Lambros MB, et al. Down-regulation of the miRNA master regulators Drosha and Dicer is associated with specific subgroups of breast cancer. Eur J Cancer 2011;47:138-50.
34. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2-ΔΔCT method. Methods 2001;25:402-8. (Pubitemid 34164012)
35. McNeill RE, Miller N, Kerin MJ. Evaluation and validation of candidate endogenous control genes for real-time quantitative PCR studies of breast cancer. BMC Mol Biol 2007;8:107.
36. Martello G, Rosato A, Ferrari F, et al. MicroRNA targeting dicer for metastasis control. Cell 2010;141:1195-207.
37. Sinkkonen L, Hugenschmidt T, Filipowicz W, et al. Dicer is associated with ribosomal DNA chromatin in mammalian cells. PLoS One 2010;5:e12175.
38. Emmerth S, Schober H, Gaidatzis D, et al. Nuclear retention of fission yeast dicer is a prerequisite for RNAi-mediated heterochromatin assembly. Dev Cell 2010;18:102-13.
39. Ando Y, Tomaru Y, Morinaga A, et al. Nuclear pore complex protein mediated nuclear localization of dicer protein in human cells. PLoS One 2011;6:e23385.
40. Schwanhäusser B, Busse D, Li N, et al. Global quantification of mammalian gene expression control. Nature 2011;473:337-42.
41. Carthew RW, Sontheimer EJ. Origins and mechanisms of miRNAs and siRNAs. Cell 2009;136:642-55.